- Home
- EDRY vs CGTX Comparison
EDRY vs CGTX Comparison
Compare EDRY & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- CGTX
- Stock Information
- Founded
- EDRY 2018
- CGTX 2007
- Country
- EDRY Greece
- CGTX United States
- Employees
- EDRY N/A
- CGTX N/A
- Industry
- EDRY Marine Transportation
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- EDRY Consumer Discretionary
- CGTX Health Care
- Exchange
- EDRY Nasdaq
- CGTX Nasdaq
- Market Cap
- EDRY 31.7M
- CGTX 30.0M
- IPO Year
- EDRY N/A
- CGTX 2021
- Fundamental
- Price
- EDRY $11.18
- CGTX $0.64
- Analyst Decision
- EDRY
- CGTX Strong Buy
- Analyst Count
- EDRY 0
- CGTX 6
- Target Price
- EDRY N/A
- CGTX $8.30
- AVG Volume (30 Days)
- EDRY 8.1K
- CGTX 891.3K
- Earning Date
- EDRY 02-18-2025
- CGTX 03-25-2025
- Dividend Yield
- EDRY N/A
- CGTX N/A
- EPS Growth
- EDRY N/A
- CGTX N/A
- EPS
- EDRY N/A
- CGTX N/A
- Revenue
- EDRY $65,085,280.00
- CGTX N/A
- Revenue This Year
- EDRY $34.61
- CGTX N/A
- Revenue Next Year
- EDRY $15.93
- CGTX N/A
- P/E Ratio
- EDRY N/A
- CGTX N/A
- Revenue Growth
- EDRY 39.04
- CGTX N/A
- 52 Week Low
- EDRY $10.04
- CGTX $0.34
- 52 Week High
- EDRY $24.84
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- EDRY 42.93
- CGTX 43.76
- Support Level
- EDRY $10.40
- CGTX $0.60
- Resistance Level
- EDRY $11.72
- CGTX $0.82
- Average True Range (ATR)
- EDRY 0.49
- CGTX 0.06
- MACD
- EDRY 0.01
- CGTX -0.02
- Stochastic Oscillator
- EDRY 37.86
- CGTX 18.56
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulks such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.